Oncurious NV Launches New Website

2 Sep 2015

Leuven, September 2, 2015 – Oncurious NV, an oncology company focused on the development of innovative medicines for the treatment of pediatric tumors, today announces the launch of its new website.

The new website provides more background on the compelling science behind the Company’s lead product TB-403 and its potential to improve the treatment of medulloblastoma, a rare life-threatening brain tumor that mainly affects children.

Oncurious NV is a joint venture between ThromboGenics and VIB, a leading life science research institute in Flanders (Belgium).